Intensity Therapeutics, Inc. (INTS)
Last updated: 2026-10-22 22:57:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Intensity Therapeutics, Inc. (INTS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.21, with a market capitalization of $10.71M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.10 to $43.50. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$10.71M | |
$3.22 | |
$286.00 | |
$3.10 | |
$3.14 | |
6.77K | |
26.62K | |
-- | |
$43.50 | |
$3.10 | |
-- | |
-- |
Intensity Therapeutics, Inc. (INTS) After-Hours Stock Price
Intensity Therapeutics, Inc. (INTS) is trading at $3.21 in after-hours trading as of 2026-10-22 20:26:00, up 1.99% ($0.06) from the regular-session close of $3.14.
After-hours trading shows how investors are pricing INTS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Intensity Therapeutics, Inc. (INTS) 7-Day Stock Price Change
Over the past seven days, Intensity Therapeutics, Inc. (INTS) moved from $3.55 to $3.21, representing a decline of 9.72% ($0.34).
The stock traded between $3.10 and $4.04 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 29.98 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
INTS 52-Week Price Position
Position in Range: 0.3%
INTS is currently trading at $3.21, placing it 0.3% of the way from its 52-week low of $3.10 to its 52-week high of $43.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Intensity Therapeutics, Inc. (INTS)?
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Intensity Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Intensity Therapeutics, Inc. (INTS) Stock on MEXC
Eligible investors can buy real shares of Intensity Therapeutics, Inc. (INTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Intensity Therapeutics, Inc. (INTS) stock price today?
2.Is INTS stock going up or down today?
3.What is INTS pre-market price?
4.What is INTS after-hours price?
5.Is INTS stock trading now?
6.Where does INTS sit relative to its 52-week high and low?
7.What sector is Intensity Therapeutics, Inc. in?
8.What is Intensity Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is INTS valued in terms of P/E ratio and EPS?
10.Does Intensity Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
INTS Stock Calculator
Estimate the value between INTS shares and USD.
INTS Shares to USD
1.00 INTS shares = 3.205 USD
Calculations are estimates based on the latest available price and are for reference only.



